| Nome |
# |
|
Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease, file de164a8f-2e50-73f5-e053-d805fe0a7be4
|
37
|
|
Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease, file de164a8e-c658-73f5-e053-d805fe0a7be4
|
29
|
|
Comparison between 1.5 and 3.0 Tesla magnetic resonance enterography for the assessment of disease activity and complications in ileo-colonic Crohn's disease, file de164a8f-25cf-73f5-e053-d805fe0a7be4
|
21
|
|
ECCO Position Paper: Harmonization of the Approach to Ulcerative Colitis Histopathology, file de164a8f-1173-73f5-e053-d805fe0a7be4
|
19
|
|
WallFlex colonic stent placement for management of malignant colonic obstruction : a prospective study at two centers, file de164a8f-2f4f-73f5-e053-d805fe0a7be4
|
11
|
|
JAK or GUT Selectivity: Tipping the Balance for Efficacy and Safety in Ulcerative Colitis, file de164a8f-1177-73f5-e053-d805fe0a7be4
|
10
|
|
Bowel damage as assessed by the Lémann Index is reversible on anti-TNF therapy for Crohn's disease, file de164a8f-1ff7-73f5-e053-d805fe0a7be4
|
9
|
|
Short-term outcomes of laparoscopy combined with enhanced recovery pathway after ileocecal resection for Crohn's disease : a case-matched analysis, file de164a8f-2079-73f5-e053-d805fe0a7be4
|
9
|
|
Endoscopic mucosal resection for early colorectal neoplasia: pathologic basis, procedures, and outcomes., file de164a8f-2b66-73f5-e053-d805fe0a7be4
|
7
|
|
VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis, file de164a8f-2c7d-73f5-e053-d805fe0a7be4
|
7
|
|
Infliximab therapy inhibits inflammation-induced angiogenesis in the mucosa of patients with Crohn's disease, file de164a8f-3390-73f5-e053-d805fe0a7be4
|
7
|
|
Vascular endothelial growth factor C disrupts the endothelial lymphatic barrier to promote colorectal cancer invasion, file de164a8e-c169-73f5-e053-d805fe0a7be4
|
6
|
|
Direct retrospective comparison of adalimumab and infliximab in preventing early postoperative endoscopic recurrence after ileocaecal resection for Crohn's disease : results from the MULTIPER database, file de164a8e-c051-73f5-e053-d805fe0a7be4
|
5
|
|
Activation of the VEGFC/VEGFR3 Pathway Induces Tumor Immune Escape in Colorectal Cancer, file de164a8e-c0e9-73f5-e053-d805fe0a7be4
|
5
|
|
Rho-A prenylation and signaling link epithelial homeostasis to intestinal inflammation, file de164a8e-c45f-73f5-e053-d805fe0a7be4
|
5
|
|
Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease : a prospective study, file de164a8f-2643-73f5-e053-d805fe0a7be4
|
5
|
|
Budesonide : teaching an old dog new tricks for inflammatory bowel disease treatment, file de164a8f-29b2-73f5-e053-d805fe0a7be4
|
5
|
|
Step-up and top-down approaches to the treatment of Crohn’s disease: early may already be too late, file de164a8f-32bc-73f5-e053-d805fe0a7be4
|
5
|
|
Prevalence of Bowel Damage Assessed by Cross-Sectional Imaging in Early Crohn's Disease and its Impact on Disease Outcome., file de164a8e-bc49-73f5-e053-d805fe0a7be4
|
3
|
|
Lymphatic endothelium contributes to colorectal cancer growth via the soluble matrisome component GDF11, file de164a8e-c5cc-73f5-e053-d805fe0a7be4
|
3
|
|
Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management, file de164a8f-0ad2-73f5-e053-d805fe0a7be4
|
3
|
|
Inflammatory Bowel Disease Management During the Coronavirus-19 Outbreak: A Survey From the European Crohn's and Colitis Organization, file de164a8f-1109-73f5-e053-d805fe0a7be4
|
3
|
|
OP018 High-fat diet and inflammation drive intestinal fibrosis enhancing epithelial–mesenchymal transition through the activation of S1P3 signalling, file de164a8f-15fc-73f5-e053-d805fe0a7be4
|
3
|
|
Clinical Trials for Inflammatory Bowel Disease: Global Guidance During the COVID-19 Pandemic, file de164a8f-17a2-73f5-e053-d805fe0a7be4
|
3
|
|
Preoperative magnetic resonance enterography in predicting findings and optimizing surgical approach in Crohn's disease, file de164a8f-25ca-73f5-e053-d805fe0a7be4
|
3
|
|
Bacterial sensor triggering receptor expressed on myeloid cells-2 regulates the mucosal inflammatory response, file de164a8f-25ce-73f5-e053-d805fe0a7be4
|
3
|
|
The Role of Magnetic Resonance Imaging in Detecting Intestinal Fibrosis in Crohn's Disease, file de164a8f-2600-73f5-e053-d805fe0a7be4
|
3
|
|
Unique role of junctional adhesion molecule-A in maintaining mucosal homeostasis in inflammatory bowel disease, file de164a8e-bcff-73f5-e053-d805fe0a7be4
|
2
|
|
COMPARATIVE ACCURACY OF US VERSUS MRI AND COLONOSCOPY IN ASSESSING DISEASE ACTIVITY AND COMPLICATIONS AND INFLUENCING THE DECISION-MAKING PROCESS IN CROHN'S DISEASE, file de164a8e-c113-73f5-e053-d805fe0a7be4
|
2
|
|
Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis, file de164a8e-c460-73f5-e053-d805fe0a7be4
|
2
|
|
Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study, file de164a8e-c4e2-73f5-e053-d805fe0a7be4
|
2
|
|
The lymphatic system controls intestinal inflammation and inflammation-associated colon cancer through the chemokine decoy receptor D6, file de164a8e-c6e4-73f5-e053-d805fe0a7be4
|
2
|
|
Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis-two cases in real world clinical practice. Authors' reply, file de164a8f-0ac9-73f5-e053-d805fe0a7be4
|
2
|
|
Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients From the Nancy and Milan Cohorts, file de164a8f-1107-73f5-e053-d805fe0a7be4
|
2
|
|
Comparative accuracy of ferritin, transferrin saturation and soluble transferrin receptor for the diagnosis of iron deficiency in inflammatory bowel disease, file de164a8f-116c-73f5-e053-d805fe0a7be4
|
2
|
|
Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis, file de164a8f-116f-73f5-e053-d805fe0a7be4
|
2
|
|
Histological Remission in Ulcerative Colitis: Under the Microscope Is the Cure, file de164a8f-13c0-73f5-e053-d805fe0a7be4
|
2
|
|
Liver tests abnormalities in COVID-19: trick or treat?, file de164a8f-13c5-73f5-e053-d805fe0a7be4
|
2
|
|
Upadacitinib for Crohn's disease and ulcerative colitis treatment: hitting the selective JAKpot, file de164a8f-156f-73f5-e053-d805fe0a7be4
|
2
|
|
Balancing Risks and Benefits in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic, file de164a8f-173c-73f5-e053-d805fe0a7be4
|
2
|
|
Thiopurines' Metabolites and Drug Toxicity: A Meta-Analysis, file de164a8f-1e02-73f5-e053-d805fe0a7be4
|
2
|
|
mTOR-Dependent Stimulation of IL20RA Orchestrates Immune Cell Trafficking through Lymphatic Endothelium in Patients with Crohn's Disease, file de164a8f-1ff9-73f5-e053-d805fe0a7be4
|
2
|
|
COVID-19 Digestive System Involvement and Clinical Outcomes in a Large Academic Hospital in Milan, Italy, file de164a8f-2375-73f5-e053-d805fe0a7be4
|
2
|
|
Imaging Modalities for Perianal Crohn's Disease, file de164a8f-2790-73f5-e053-d805fe0a7be4
|
2
|
|
Anti-adhesion molecule therapies in inflammatory bowel disease: touch and go, file de164a8f-33c8-73f5-e053-d805fe0a7be4
|
2
|
|
Integrated models of care in managing inflammatory bowel disease: a discussion., file de164a8e-bc61-73f5-e053-d805fe0a7be4
|
1
|
|
Surgical rates in the era of biological therapy: up, down or unchanged?, file de164a8e-bc8f-73f5-e053-d805fe0a7be4
|
1
|
|
New insights into inflammatory bowel disease pathophysiology: Paving the way for novel therapeutic targets, file de164a8e-bceb-73f5-e053-d805fe0a7be4
|
1
|
|
Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease, file de164a8e-bcee-73f5-e053-d805fe0a7be4
|
1
|
|
Inflammation and coagulation in inflammatory bowel disease: The clot thickens, file de164a8e-bcef-73f5-e053-d805fe0a7be4
|
1
|
|
Review article: anti-fibrotic agents for the treatment of Crohn's disease - lessons learnt from other diseases, file de164a8e-bcfa-73f5-e053-d805fe0a7be4
|
1
|
|
Oral Beclomethasone: A Review of its Use in Inflammatory Bowel Disease, file de164a8e-bcfe-73f5-e053-d805fe0a7be4
|
1
|
|
The impact of biologics in surgical outcomes in ulcerative colitis, file de164a8e-bdef-73f5-e053-d805fe0a7be4
|
1
|
|
Identification of serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease, file de164a8e-bea4-73f5-e053-d805fe0a7be4
|
1
|
|
Are Surgical Rates Decreasing in the Biological Era In IBD?, file de164a8e-bec5-73f5-e053-d805fe0a7be4
|
1
|
|
Biological agents for ulcerative colitis : Hypes and hopes, file de164a8e-bfaf-73f5-e053-d805fe0a7be4
|
1
|
|
Calcium supplementation for the prevention of colorectal adenomas: a systematic review and meta-analysis of randomized controlled trials, file de164a8e-bfc7-73f5-e053-d805fe0a7be4
|
1
|
|
Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn's and Ulcerative Colitis Associations, file de164a8e-bfef-73f5-e053-d805fe0a7be4
|
1
|
|
Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial, file de164a8e-bff2-73f5-e053-d805fe0a7be4
|
1
|
|
Regulation of leukocyte recruitment by the long pentraxin PTX3., file de164a8e-c01d-73f5-e053-d805fe0a7be4
|
1
|
|
Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA, file de164a8e-c091-73f5-e053-d805fe0a7be4
|
1
|
|
Risk factors for complications after ileocolonic resection for Crohn's disease with a major focus on the impact of preoperative immunosuppressive and biologic therapy: A retrospective international multicentre study., file de164a8e-c0dd-73f5-e053-d805fe0a7be4
|
1
|
|
Dose Optimization Is Effective in Patients With Ulcerative Colitis Losing Response to Infliximab: A Collaborative Multicentre Retrospective Study, file de164a8e-c0f3-73f5-e053-d805fe0a7be4
|
1
|
|
Role of bowel ultrasound as a predictor of surgical recurrence of Crohn's disease, file de164a8e-c0f4-73f5-e053-d805fe0a7be4
|
1
|
|
Ulcerative Colitis, file de164a8e-c0f9-73f5-e053-d805fe0a7be4
|
1
|
|
Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study, file de164a8e-c107-73f5-e053-d805fe0a7be4
|
1
|
|
Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients, file de164a8e-c1dc-73f5-e053-d805fe0a7be4
|
1
|
|
Infliximab in Steroid-Dependent Ulcerative Colitis: Efficacy and Predictors of Clinical and Endoscopic Remission, file de164a8e-c335-73f5-e053-d805fe0a7be4
|
1
|
|
Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial, file de164a8e-c424-73f5-e053-d805fe0a7be4
|
1
|
|
Multimodal treatment of perianal fistulas in Crohn's disease: seton versus anti-TNF versus advancement plasty (PISA): study protocol for a randomized controlled trial, file de164a8e-c43f-73f5-e053-d805fe0a7be4
|
1
|
|
Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease, file de164a8e-c4de-73f5-e053-d805fe0a7be4
|
1
|
|
The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy, file de164a8e-c4e0-73f5-e053-d805fe0a7be4
|
1
|
|
Methylene blue MMX (R) tablets for chromoendoscopy. Safety tolerability and bioavailability in healthy volunteers, file de164a8e-c53c-73f5-e053-d805fe0a7be4
|
1
|
|
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission, file de164a8e-c5b4-73f5-e053-d805fe0a7be4
|
1
|
|
Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease, file de164a8e-c5bb-73f5-e053-d805fe0a7be4
|
1
|
|
New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease, file de164a8e-c5c0-73f5-e053-d805fe0a7be4
|
1
|
|
Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2, file de164a8e-c659-73f5-e053-d805fe0a7be4
|
1
|
|
Antibodies to infliximab in patients treated with either the reference biologic or the biosimilar CT-P13 show identical reactivity towards biosimilars CT-P13 and SB2 in inflammatory bowel disease, file de164a8e-c743-73f5-e053-d805fe0a7be4
|
1
|
|
Adalimumab in active ulcerative colitis: A "real-life" observational study, file de164a8e-c748-73f5-e053-d805fe0a7be4
|
1
|
|
Surgical conduct in case of intraoperative detection of a Meckel's diverticulum in Crohn's disease, file de164a8e-d959-73f5-e053-d805fe0a7be4
|
1
|
|
Colorectal cancer in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (I), file de164a8e-f270-73f5-e053-d805fe0a7be4
|
1
|
|
Stimulation of CYP450-mediated ω-3 docosahexaenoic acid metabolism via MFSD2A as a novel therapy for inflammatory bowel disease, file de164a8e-ffc6-73f5-e053-d805fe0a7be4
|
1
|
|
Phase I, II and III Trials in Inflammatory Bowel Diseases: A Practical Guide for the Non-specialist, file de164a8f-0ac5-73f5-e053-d805fe0a7be4
|
1
|
|
Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey, file de164a8f-0acd-73f5-e053-d805fe0a7be4
|
1
|
|
Author response to: Covid-19-related pancreatic injury, file de164a8f-1102-73f5-e053-d805fe0a7be4
|
1
|
|
Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' reply, file de164a8f-116a-73f5-e053-d805fe0a7be4
|
1
|
|
Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease, file de164a8f-11da-73f5-e053-d805fe0a7be4
|
1
|
|
New Drugs in the Ulcerative Colitis Pipeline: Prometheus Unbound, file de164a8f-13bd-73f5-e053-d805fe0a7be4
|
1
|
|
Use of Cross-Sectional Imaging for Tight Monitoring of Inflammatory Bowel Diseases, file de164a8f-13bf-73f5-e053-d805fe0a7be4
|
1
|
|
Inflammatory Bowel Diseases and COVID-19: The Invisible Enemy, file de164a8f-150b-73f5-e053-d805fe0a7be4
|
1
|
|
Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period, file de164a8f-150d-73f5-e053-d805fe0a7be4
|
1
|
|
Maintaining the Quality Standards of Care for Inflammatory Bowel Disease Patients During the COVID-19 Pandemic, file de164a8f-150f-73f5-e053-d805fe0a7be4
|
1
|
|
Inflammatory Bowel Disease Care in the COVID-19 Pandemic Era: The Humanitas, Milan, Experience, file de164a8f-15ce-73f5-e053-d805fe0a7be4
|
1
|
|
SFED recommendations for IBD endoscopy during COVID-19 pandemic: Italian and French experience, file de164a8f-15f4-73f5-e053-d805fe0a7be4
|
1
|
|
Fibroblast Growth Factor 19 modulates intestinal microbiota and inflammation in presence of Farnesoid X Receptor, file de164a8f-173d-73f5-e053-d805fe0a7be4
|
1
|
|
Protecting patients with IBD during the COVID-19 pandemic, file de164a8f-179e-73f5-e053-d805fe0a7be4
|
1
|
|
Tofacitinib for Acute Severe Colitis: When the going Gets Tough, the Tough Get Going, file de164a8f-19d3-73f5-e053-d805fe0a7be4
|
1
|
|
More on Covid-19 in Immune-Mediated Inflammatory Diseases, file de164a8f-1cd8-73f5-e053-d805fe0a7be4
|
1
|
|
Point-of-Care Ultrasound in Inflammatory Bowel Disease, file de164a8f-1ef0-73f5-e053-d805fe0a7be4
|
1
|
|
MFSD2A Promotes Endothelial Generation of Inflammation-resolving Lipid Mediators and Reduces Colitis in Mice, file de164a8f-2436-73f5-e053-d805fe0a7be4
|
1
|
| Totale |
320 |